Myra K. Casey
FDA investigator
Appears on 5 documents from 2002 to 2020, mostly at sites in Indiana. Most often cites postmarketing reporting of adverse drug experiences (21 CFR 314.80(c)(2)).
- 5
- Documents on file
- 1.0
- Observations per 483
- 2002
- First seen
- 2020
- Most recent
What they cite most
From 2 observations- 21 CFR 314.80(c)(2)Postmarketing reporting of adverse drug experiences1
Activity by year
2002: 1, 2008: 1, 2018: 1, 2020: 2
Where
Indiana 4 · Michigan 1
Often inspects with
Is Myra K. Casey coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
5 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2020-03-20 | EIR Eli Lilly and CompanyMar 20, 2020 · Indianapolis, Indiana | Indianapolis, Indiana | — | |
| 2020-01-17 | EIR Eli Lilly and CompanyJan 17, 2020 · Indianapolis, Indiana | Indianapolis, Indiana | — | |
| 2018-04-23 | 483 Eli Lilly and CompanyApr 23, 2018 · Indianapolis, Indiana | Indianapolis, Indiana | 1 | |
| 2008-01-28 | EIR Depuy Orthopaedics, IncJan 28, 2008 · Warsaw, Indiana | Warsaw, Indiana | — | |
| 2002-09-13 | 483 Emergent Biodefense Operations Lansing LLCSep 13, 2002 · Lansing, Michigan | Lansing, Michigan | — |
About this profile
What does Myra K. Casey inspect?
Myra K. Casey appears on 5 documents on file covering 3 sites, mostly in Indiana.
What do they cite most often?
21 CFR 314.80(c)(2) (postmarketing reporting of adverse drug experiences).
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Myra K. Casey is dated Mar 20, 2020.